PATENT CLAIM ANALYSIS

Application Number: 15745329
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "235800"]

Abstract:
The present disclosure relates to aniline pyrimidine derivatives or pharmaceutically acceptable salts thereof as EGFR inhibitors, specifically relates to compounds represented by formula (I) or pharmaceutically acceptable salts, pharmaceutical compositions, the method and uses thereof for treating EGFR mediated diseases.

Claim (Index 3):
The compound represented by Formula (I) or a pharmaceutically acceptable salt thereof according to  claim 1 , characterized in that:\n X is selected from the group consisting of NR 6  and O; R 1  and R 2  are independently selected from the group consisting of hydrogen, chloro, bromo, fluoro and methyl; R 3  is methoxy; R 4  is selected from the group consisting of [2-(dimethylamino)ethyl](methyl)amino, (2-hydroxyethyl)(methyl)amino and morpholin-4-yl; R 5  is selected from the group consisting of hydrogen and methoxymethyl; R 6  is selected from the group consisting of hydrogen and methyl.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 86.0
- Lexical Diversity: 1.27778
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15517193', '15329044', '15534838', '16062399', '14881930']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8315117300191099
- 35 USC 102 Novelty (BERT): 0.5225217128311835
- Combined Prediction Score: 0.8006127283003173
- Mean Citation Score: 335.94323999999995
- Max Citation Score: 343.88495
- Similarity Product: 286.4647531275749

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test